줄기세포 제대혈 시장 규모, 점유율, 동향 분석 보고서 : 공급원별, 서비스별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Stem Cell Umbilical Cord Blood Market Summary

The global stem cell umbilical cord blood market size was valued at USD 2.2 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 3.4 billion by 2033, at a CAGR of 6.0% from 2026 to 2033. The North America market dominated the market, accounting for a revenue share of 49.2% in 2025. The significant factors contributing to market growth include the rising prevalence of hematological and genetic disorders, growing adoption of regenerative medicine and stem cell therapies, and increasing awareness and expansion of public and private cord blood banking.

Global Stem Cell Umbilical Cord Blood Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global stem cell umbilical cord blood market report by source, service, application, end use, and region:

• Source Outlook (Revenue, USD Million, 2021 - 2033)
• Umbilical Cord Blood
• Umbilical Cord Tissue
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Collection & Transportation
• Processing
• Testing
• Cryopreservation & Storage
• Sample Retrieval & Distribution
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Hematological Malignancies
• Blood Disorders
• Immune Disorders
• Metabolic Disorders
• Regenerative Medicine
• Clinical Research
• Other Applications
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Transplant Centers
• Cord Blood Banks
• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Other End User
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Source
  • 1.2.2. Service
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Hematological and Genetic Disorders
    • 3.2.1.2. Growing Adoption of Regenerative Medicine and Stem Cell Therapies
    • 3.2.1.3. Increasing Awareness and Expansion of Public & Private Cord Blood Banking
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Costs Associated with Cord Blood Banking
    • 3.2.2.2. Ethical, Regulatory, and Utilization Challenges
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Technology Overview
  • 3.2.6. Case Studies
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape

Chapter 4. Stem Cell Umbilical Cord Blood Market: Source Estimates & Trend Analysis

• 4.1. Source Segment Dashboard
• 4.2. Source Market Share Movement Analysis, 2025 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Source, 2021 to 2033 (USD Billion)
• 4.4. Umbilical Cord Blood
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.5. Umbilical Cord Tissues
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Stem Cell Umbilical Cord Blood Market: Service Estimates & Trend Analysis

• 5.1. Service Dashboard
• 5.2. Tissue Tye Market Share Movement Analysis, 2025 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Service, 2021 to 2033 (USD Billion)
• 5.4. Collection & Transportation
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.5. Processing
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.6. Testing
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.7. Cryopreservation & Storage
  • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.8. Sample Retrieval & Distribution
  • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Stem Cell Umbilical Cord Blood Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Application Market Share Movement Analysis, 2025 & 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Billion)
• 6.4. Hematological Malignancies
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.5. Blood Disorders
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.6. Immune Disorders
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.7. Metabolic Disorders
  • 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.8. Regenerative Medicine
  • 6.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.9. Clinical Research
  • 6.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.10. Other Applications
  • 6.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Stem Cell Umbilical Cord Blood Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. End use Market Share Movement Analysis, 2025 & 2033
• 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
• 7.4. Hospitals & Transplant Centers
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.5. Cord Blood Banks
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Research & Academic Institutes
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.7. Biotechnology & Pharmaceutical Companies
  • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.8. Other End User
  • 7.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Stem Cell Umbilical Cord Blood Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market: Key Takeaways
• 8.3. North America
  • 8.3.1. North America stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.3.2. U.S.
    • 8.3.2.1. Key country dynamic
    • 8.3.2.2. Regulatory framework
    • 8.3.2.3. Competitive insights
    • 8.3.2.4. U.S. stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.3.3. Canada
    • 8.3.3.1. Key country dynamic
    • 8.3.3.2. Regulatory framework
    • 8.3.3.3. Competitive insights
    • 8.3.3.4. Canada stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.3.4. Mexico
    • 8.3.4.1. Key country dynamic
    • 8.3.4.2. Regulatory framework
    • 8.3.4.3. Competitive insights
    • 8.3.4.4. Mexico stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
• 8.4. Europe
  • 8.4.1. Europe stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamic
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive insights
    • 8.4.2.4. Germany stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.3. UK
    • 8.4.3.1. Key country dynamic
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive insights
    • 8.4.3.4. UK stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.4. France
    • 8.4.4.1. Key country dynamic
    • 8.4.4.2. Regulatory framework
    • 8.4.4.3. Competitive insights
    • 8.4.4.4. France stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.5. Italy
    • 8.4.5.1. Key country dynamic
    • 8.4.5.2. Regulatory framework
    • 8.4.5.3. Competitive insights
    • 8.4.5.4. Italy stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.6. Spain
    • 8.4.6.1. Key country dynamic
    • 8.4.6.2. Regulatory framework
    • 8.4.6.3. Competitive insights
    • 8.4.6.4. Spain stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.7. Denmark
    • 8.4.7.1. Key country dynamic
    • 8.4.7.2. Regulatory framework
    • 8.4.7.3. Competitive insights
    • 8.4.7.4. Denmark stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.8. Sweden
    • 8.4.8.1. Key country dynamic
    • 8.4.8.2. Regulatory framework
    • 8.4.8.3. Competitive insights
    • 8.4.8.4. Sweden stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.4.9. Norway
    • 8.4.9.1. Key country dynamic
    • 8.4.9.2. Regulatory framework
    • 8.4.9.3. Competitive insights
    • 8.4.9.4. Norway stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.5.2. Japan
    • 8.5.2.1. Key country dynamic
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive insights
    • 8.5.2.4. Japan stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.5.3. China
    • 8.5.3.1. Key country dynamic
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive insights
    • 8.5.3.4. China stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.5.4. India
    • 8.5.4.1. Key country dynamic
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive insights
    • 8.5.4.4. India stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamic
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive insights
    • 8.5.5.4. South Korea stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.5.6. Australia
    • 8.5.6.1. Key country dynamic
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive insights
    • 8.5.6.4. Australia stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.5.7. Thailand
    • 8.5.7.1. Key country dynamic
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Competitive insights
    • 8.5.7.4. Thailand stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
• 8.6. Latin America
  • 8.6.1. Latin America Stem Cell Umbilical Cord Blood Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.2. Brazil
    • 8.6.2.1. Key country dynamic
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive insights
    • 8.6.2.4. Brazil stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamic
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive insights
    • 8.6.3.4. Argentina stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
• 8.7. MEA
  • 8.7.1. MEA stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.7.2. South Africa
    • 8.7.2.1. Key country dynamic
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive insights
    • 8.7.2.4. South Africa stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key country dynamic
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Competitive insights
    • 8.7.3.4. Saudi Arabia stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.7.4. UAE
    • 8.7.4.1. Key country dynamic
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Competitive insights
    • 8.7.4.4. UAE stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key country dynamic
    • 8.7.5.2. Regulatory framework
    • 8.7.5.3. Competitive insights
    • 8.7.5.4. Kuwait stem cell umbilical cord blood market estimates and forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position/Share Analysis (2025)
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. CooperSurgical (Cord Blood Registry)
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product/ service benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Revvity (ViaCord)
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Product/ service benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Cryo-Cell International, Inc.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product/ service benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. StemCyte Inc.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product/ service benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. FamiCord Group
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product/ service benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. Cordlife Group Limited
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product/ service benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Cells4Life Group LLP
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product/ service benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Future Health Biobank
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product/ service benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. Smart Cells
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Product/ service benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. Global Cord Blood Corporation
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product/ service benchmarking
    • 9.5.10.4. Strategic initiatives